



0300  
#4

Patent Application  
Attorney Docket No. PC10769A

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450 on this 6th day of June, 2003.

By

*Kristina L. Konstas*

(Signature of person mailing)

Kristina L. Konstas

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Mark A. Sanner, et al. :

APPLICATION NO.: 09/941,001 : Examiner: Not yet assigned

FILING DATE: August 28, 2001 : Group Art Unit: Not yet assigned

TITLE: PYRAZOLE DERIVATIVES :

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicants herein make available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the following references cited by the applicants, copies of which are enclosed.

1. WO 99/58526, Don Wha Pharm. Ind. Co, Ltd., November 18, 1999;
2. WO 99/62506, Zeneca Limited, December 9, 1999;
3. WO 99/32106, Bayer Corporation, July 1, 1999;
4. WO 01/12189, Pharmacia & Upjohn S.P.A., February 22, 2001;
5. WO 01/12188, Pharmacia & Upjohn S.P.A., February 22, 2001;
6. WO 01/07411, Banyu Pharma Co. Ltd., February 1, 2001;
7. WO 01/40215, Pfizer Products Inc., June 7, 2001;
8. WO 01/79198, Agouron Pharmaceuticals Inc., October 25, 2001;
9. Achour, R., et al., Synthesis of new adamantylated heterocycles, STN Database accession no. 122:81333 XP002183639 & Synth. Comm. (1994), 24(20), 2899-905;

10. Dumas, J. et al., 1-Phenyl-5-pyrazolyl ureas: potent and selective p38 kinase inhibitors, Bioorganic & Medicinal Chemistry Letters, Oxford, GB, vol. 10, no. 18, Sept. 2000, pp. 2051-2054;
11. Traxler, P. et al., Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo3,4-dpyrimidines, Journal of Medicinal Chemistry, American Chemical Society, vol. 40, no. 22, 1997, pp. 3601-3636;
12. Brinkmeyer, Raymond S., et al., Dimerization of pyrazolyl-5-hydroxypyrrolidinones to tetrazocines, STN Database accession no. 112:216898 & J. Heterocycl. Chem (1989), 26(6), 117-17;
13. Smadis, J., et al., Tetrahedron Elsevier sc. Pub. Amsterdam. NI Vol., 4 No. 13/08/1998, pages 9799-9810; and
14. United States 3,963,742, Cross et al., June 15, 1976.

Items 1-12 were listed in the International Search Report (ISR) issued by the European Patent Office acting as International Searching Authority in connection with a Patent Cooperation Treaty application, PCT/IB01/01540, corresponding to the subject application. A copy of said ISR is also enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a).

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

Please charge all appropriate fees to cover this submission to Pfizer Deposit Account No. 16-1445.


A prompt and favorable response is earnestly solicited.

Date: June 6, 2003

Respectfully submitted,

Kristina L. Konstas  
Kristina L. Konstas  
Attorney for Applicant(s)  
Reg. No. 37,864

Pfizer Inc  
Patent Department, 5th Floor  
150 East 42nd Street  
New York, NY 10017-5755  
(212)733-6380



Patent Application  
Attorney Docket No. PC10769A

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450 on this 6th day of June, 2003.

By

*Kristina L. Konstas*

(Signature of person mailing)  
Kristina L. Konstas

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Mark A. Sanner, et al. :

APPLICATION NO.: 09/941,001 : Examiner: Not yet assigned

FILING DATE: August 28, 2001 : Group Art Unit: Not yet assigned

TITLE: PYRAZOLE DERIVATIVES :

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicants herein make available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the following references cited by the applicants, copies of which are enclosed.

1. WO 99/58526, Don Wha Pharm. Ind. Co, Ltd., November 18, 1999;
2. WO 99/62506, Zeneca Limited, December 9, 1999;
3. WO 99/32106, Bayer Corporation, July 1, 1999;
4. WO 01/12189, Pharmacia & Upjohn S.P.A., February 22, 2001;
5. WO 01/12188, Pharmacia & Upjohn S.P.A., February 22, 2001;
6. WO 01/07411, Banyu Pharma Co. Ltd., February 1, 2001;
7. WO 01/40215, Pfizer Products Inc., June 7, 2001;
8. WO 01/79198, Agouron Pharmaceuticals Inc., October 25, 2001;
9. Achour, R., et al., Synthesis of new adamantylated heterocycles, STN Database accession no. 122:81333 XP002183639 & Synth. Comm. (1994), 24(20), 2899-905;

10. Dumas, J. et al., 1-Phenyl-5-pyrazolyl ureas: potent and selective p38 kinase inhibitors, Bioorganic & Medicinal Chemistry Letters, Oxford, GB, vol. 10, no. 18, Sept. 2000, pp. 2051-2054;
11. Traxler, P. et al., Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo3,4-dpyrimidines, Journal of Medicinal Chemistry, American Chemical Society, vol. 40, no. 22, 1997, pp. 3601-3636;
12. Brinkmeyer, Raymond S., et al., Dimerization of pyrazolyl-5-hydroxypyrrolidinones to tetrazocines, STN Database accession no. 112:216898 & J. Heterocycl. Chem (1989), 26(6), 117-17;
13. Smodis, J., et al., Tehrahedron elserir sc. Pub. Amsterdam. NI Vol., 4 No. 13/08/1998, pages 9799-9810; and
14. United States 3,963,742, Cross et al., June 15, 1976.

Items 1-12 were listed in the International Search Report (ISR) issued by the European Patent Office acting as International Searching Authority in connection with a Patent Cooperation Treaty application, PCT/IB01/01540, corresponding to the subject application. A copy of said ISR is also enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a).

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

Please charge all appropriate fees to cover this submission to Pfizer Deposit Account No. 16-1445.

A prompt and favorable response is earnestly solicited.


Date: June 6, 2003

Respectfully submitted,



Kristina L. Konstas  
Attorney for Applicant(s)  
Reg. No. 37,864

Pfizer Inc  
Patent Department, 5th Floor  
150 East 42nd Street  
New York, NY 10017-5755  
(212)733 -6380



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)										ATTY. DOCKET NO. PC10769A					SERIAL NO. 09/941,001									
										APPLICANT Mark A. Sanner, et al.														
										FILING DATE August 28, 2001					GROUP Not yet assigned									
U.S. PATENT DOCUMENTS																								
EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE											
	US	3	9	6	3	7	4	2	06/15/76	Cross, et al.														
FOREIGN PATENT DOCUMENTS																								
DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION											
													YES	NO										
		9	9	5	8	5	2	6	11/18/99	WO														
		9	9	6	2	5	0	6	12/9/99	WO														
		9	9	3	2	1	0	6	4/1/99	WO														
		0	1	1	2	1	8	9	2/22/01	WO														
		0	1	1	2	1	8	8	02/22/01	WO														
		0	1	0	7	4	1	1	2/1/01	WO														
		0	1	4	0	2	1	5	6/7/01	WO														
		0	1	7	9	1	9	8	10/25/01	WO														
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)																								
		Archour, R., et al., Synthesis of new adamantylated heterocycles, STN Database accession no. 122:81333 XP002183639 & Synth. Comm. (1994), 24(20), 2899-905.																						
		Dumas, J. et al., 1-phenyl-5-pyrazolyl ureas: potent and selective p38 kinase inhibitors, Biorganic & Medicinal Chemistry Letters, Oxford, GB, vol. 10, no. 18, Sept. 2000, pp. 2051-2054.																						
		Traxler, P., et al., Use of a pharmacophore model for the design of EGR-R tyrosine kinase inhibitors: 4-(phenylaminopyrazolo 3,4-dpyrimidines, Journal of Medicinal Chemistry, American Chemical Society, vol. 40, no. 22, 1997, pp. 3601-3636.																						
		Brinkmeyer, Raymond S., et al., Dimerization of pyrazolyl-5-hydrosypyrrolidinones to tetrazocines, STN Database accession no. 112:216898 & J. Heterocycl. Chem (1989), 26(6), 117-17.																						
		Smodis, J., et al., Tehradron elserir sc. Pub. Amsterdam. NI Vol., 4 No. 13/08/1998, pages 9799-9810.																						
EXAMINER										DATE CONSIDERED														
Not yet assigned																								
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.																								